Sividon Diagnostics
Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.
Myriad Genetics Adds Breast Cancer Prognostic Dx to Portfolio Through Sividon Acquisition
The acquisition provides Myriad with the EndoPredict test, which is currently offered in Europe and is expected to launch in the US next year.
Study Suggests EndoPredict Clinical Score Outperforms Oncotype DX for Assessing Late Recurrence
Premium
The analysis showed that one out of 227 node-negative breast cancer patients with the lowest EPclin scores by Sividon's EndoPredict test experienced recurrence over 10 years.
At the San Antonio Breast Cancer Symposium, a Sividon collaborator is scheduled to present a new study including a comparison between EndoPredict and Oncotype DX.